On-Demand Webinar: Beyond Traditional Cost-Effectiveness Analysis-- The Importance of Novel Value Components
This unique webinar addresses current standards of cost-effectiveness analysis- including limitations and challenges- and reviews often overlooked sources of value and the importance of these alternative value assessments in discussions with payers, policymakers, and other stakeholders (w/Q&A session following webinar presentation).
Darius Lakdawalla, PhD
PHE Chief Scientific Officer
Tiffany Shih, PhD
PHE Research Economist
Click the link here to register and stream the on-demand webinar.
By: Jason Shafrin, PhD Sr. Director, Policy and Economics and Jacki Chou, MPL Senior Director, Policy and Economics The recent announcement that CVS Caremark will use value-based metrics to inform formulary design at first appears a step in the right direction. However, using value measurements from a single nongovernmental organization—the Institute for Clinical and Economic Review (ICER)—based on a limited picture of treatment value may be problematic. Using this single assessment of value in an effort solely to exclude drugs from a major insurance formulary is even more worrisome and fails to recognize the heterogeneity in patient clinical needs and preferences.